Form 25-NSE - Notification filed by national security exchange to report the removal from listing and registration of matured, redeemed or retired securities:
SEC Accession No. 0001143313-24-000012
Filing Date
2024-01-16
Accepted
2024-01-16 13:53:16
Documents
2
Effectiveness Date
2024-01-16

Document Format Files

Seq Description Document Type Size
1 primary_doc.html 25-NSE  
1 primary_doc.xml 25-NSE 1086
2 ruleprovisionnotice.htm EX-99.25 2255
  Complete submission text file 0001143313-24-000012.txt   5331
Mailing Address 4995 BRADENTON AVENUE SUITE 240 DUBLIN OH 43017
Business Address 4995 BRADENTON AVENUE SUITE 240 DUBLIN OH 43017 6147937500
NAVIDEA BIOPHARMACEUTICALS, INC. (Subject) CIK: 0000810509 (see all company filings)

EIN.: 311080091 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 25-NSE | Act: 34 | File No.: 001-35076 | Film No.: 24534654
SIC: 2835 In Vitro & In Vivo Diagnostic Substances
(CF Office: 03 Life Sciences)

Mailing Address 11 Wall Street New York NY 10005
Business Address 11 Wall Street New York NY 10005 212-656-5414
NYSE AMERICAN LLC (Filed by) CIK: 0001143313 (see all company filings)

EIN.: 522127241
Type: 25-NSE